Answers are grounded in this paper and cite their sources.
Discovering novel therapies and defining the causal contribution of genes, proteins and lipids is challenging in sepsis, because sepsis is so heterogeneous; effective therapies in one patient may not be effective in another, explaining in part why sepsis trials have not been very successful.We highlight Mendelian randomization (MR), a statistical methods that first helps establish causal relationships between intermediate phenotypes such as plasma proteins and clinical phenotypes using genetics.In sepsis, there are innumerable studies showing significant associations between proteins, metabolites, other biomarkers and outcomes, yet the causal contribution of biomarkers is highly uncertain, potentially due to confounding, reverse causation, or because, for example, inflammatory markers are non-specific epiphenomena.Genetics are a powerful tool to interrogate which intermediate traits, including plasma proteins, metabolites, or even radiographic features, contribute to a disease.MR also enhances prognostic and predictive enrichment of sepsis trials by better defining biologically relevant clinical subgroups.The technique has been successfully used to define several traits with causal contributions to risk for acute respiratory distress syndrome (ARDS) [1-3] and to sepsis mortality [4, 5], highlighting pathways which warrant targeting and identifying specific at-risk populations.Thus, MR holds promise to advance successful precision sepsis trials.
No takes yet. Share an insight, caveat, or question.
Russell et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: